These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 27156625)
21. Detection of Rifampicin- and Isoniazid-Resistant Mycobacterium tuberculosis Using the Quantamatrix Multiplexed Assay Platform System. Wang HY; Uh Y; Kim S; Cho E; Lee JS; Lee H Ann Lab Med; 2018 Nov; 38(6):569-577. PubMed ID: 30027701 [TBL] [Abstract][Full Text] [Related]
22. Emergence and selection of isoniazid and rifampin resistance in tuberculosis granulomas. Pienaar E; Linderman JJ; Kirschner DE PLoS One; 2018; 13(5):e0196322. PubMed ID: 29746491 [TBL] [Abstract][Full Text] [Related]
23. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in iran. Velayati AA; Masjedi MR; Farnia P; Tabarsi P; Ghanavi J; ZiaZarifi AH; Hoffner SE Chest; 2009 Aug; 136(2):420-425. PubMed ID: 19349380 [TBL] [Abstract][Full Text] [Related]
24. Detection of and treatment protocol for rifampicin-monoresistant tuberculosis: what is the role of isoniazid? Velayati AA; Farnia P; Masjedi MR; Hoffner S Int J Tuberc Lung Dis; 2013 Jun; 17(6):849-50. PubMed ID: 23676176 [No Abstract] [Full Text] [Related]
25. Prognostic significance of novel Valafar F; Ramirez-Busby SM; Torres J; Paul LV; Rodwell TC; Victor TC; Rodrigues C; Gler MT; Crudu V; Catanzaro T Int J Mycobacteriol; 2015 Mar; 4(Suppl 1):51-52. PubMed ID: 27695670 [TBL] [Abstract][Full Text] [Related]
26. Prevalence of anti-tuberculosis drug resistance in foreign-born tuberculosis cases in the U.S. and in their countries of origin. Taylor AB; Kurbatova EV; Cegielski JP PLoS One; 2012; 7(11):e49355. PubMed ID: 23145161 [TBL] [Abstract][Full Text] [Related]
27. Clinical characteristics and treatment outcomes of patients with low- and high-concentration isoniazid-monoresistant tuberculosis. Wang TY; Lin SM; Shie SS; Chou PC; Huang CD; Chung FT; Kuo CH; Chang PJ; Kuo HP PLoS One; 2014; 9(1):e86316. PubMed ID: 24466020 [TBL] [Abstract][Full Text] [Related]
28. Drug-resistance of Mycobacterium tuberculosis in Patras, Greece. Trakada G; Tsiamita M; Spiropoulos K Monaldi Arch Chest Dis; 2004; 61(1):65-70. PubMed ID: 15366340 [TBL] [Abstract][Full Text] [Related]
29. Primary and secondary anti-tuberculosis drug resistance in Hitossa District of Arsi Zone, Oromia Regional State, Central Ethiopia. Hamusse SD; Teshome D; Hussen MS; Demissie M; Lindtjørn B BMC Public Health; 2016 Jul; 16():593. PubMed ID: 27430266 [TBL] [Abstract][Full Text] [Related]
30. Isoniazid preventive therapy and risk for resistant tuberculosis. Balcells ME; Thomas SL; Godfrey-Faussett P; Grant AD Emerg Infect Dis; 2006 May; 12(5):744-51. PubMed ID: 16704830 [TBL] [Abstract][Full Text] [Related]
31. Isoniazid-phytochemical conjugation: A new approach for potent and less toxic anti-TB drug development. Swain SS; Paidesetty SK; Padhy RN; Hussain T Chem Biol Drug Des; 2020 Aug; 96(2):714-730. PubMed ID: 32237023 [TBL] [Abstract][Full Text] [Related]
32. Molecular and phenotypic characterisation of Mycobacterium tuberculosis resistant to anti-tuberculosis drugs. Imperiale BR; Zumárraga MJ; Di Giulio AB; Cataldi AA; Morcillo NS Int J Tuberc Lung Dis; 2013 Aug; 17(8):1088-93. PubMed ID: 23827034 [TBL] [Abstract][Full Text] [Related]
33. Isoniazid-monoresistant tuberculosis in France: Risk factors, treatment outcomes and adverse events. Bachir M; Guglielmetti L; Tunesi S; Billard-Pomares T; Chiesi S; Jaffré J; Langris H; Pourcher V; Schramm F; Lemaître N; Robert J; Int J Infect Dis; 2021 Jun; 107():86-91. PubMed ID: 33823278 [TBL] [Abstract][Full Text] [Related]
34. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis]. Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568 [TBL] [Abstract][Full Text] [Related]
35. Longitudinal whole genome analysis of pre and post drug treatment Mycobacterium tuberculosis isolates reveals progressive steps to drug resistance. Datta G; Nieto LM; Davidson RM; Mehaffy C; Pederson C; Dobos KM; Strong M Tuberculosis (Edinb); 2016 May; 98():50-5. PubMed ID: 27156618 [TBL] [Abstract][Full Text] [Related]
36. Trends of drug resistant Mycobacterium tuberculosis in a tertiary tuberculosis center in Iran. Mirsaeidi MS; Tabarsi P; Farnia P; Ebrahimi G; Morris MW; Masjedi MR; Velayati AA; Mansouri D Saudi Med J; 2007 Apr; 28(4):544-50. PubMed ID: 17457475 [TBL] [Abstract][Full Text] [Related]
37. Surveillance of Mycobacterium tuberculosis drug resistance in Hong Kong, 1986-1999, after the implementation of directly observed treatment. Kam KM; Yip CW Int J Tuberc Lung Dis; 2001 Sep; 5(9):815-23. PubMed ID: 11573892 [TBL] [Abstract][Full Text] [Related]
38. Effect of drug resistance on the generation of secondary cases of tuberculosis. Burgos M; DeRiemer K; Small PM; Hopewell PC; Daley CL J Infect Dis; 2003 Dec; 188(12):1878-84. PubMed ID: 14673768 [TBL] [Abstract][Full Text] [Related]
39. SILA-421 activity in vitro against rifampicin-susceptible and rifampicin-resistant Mycobacterium tuberculosis, and in vivo in a murine tuberculosis model. de Knegt GJ; Bakker-Woudenberg IA; van Soolingen D; Aarnoutse R; Boeree MJ; de Steenwinkel JE Int J Antimicrob Agents; 2015 Jul; 46(1):66-72. PubMed ID: 25951996 [TBL] [Abstract][Full Text] [Related]
40. Quantifying the burden and trends of isoniazid resistant tuberculosis, 1994-2009. Jenkins HE; Zignol M; Cohen T PLoS One; 2011; 6(7):e22927. PubMed ID: 21829557 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]